Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
ln Vitro |
A new fungal surrogate marker, (1–3)-β-D glucan, offers a noninvasive method for the potential surveillance and diagnosis of invasive fungal infections. Invasive fungal infections have long been associated with significantly high morbidity and mortality on hematology-oncology wards and recipients of either solid-organ or hematopoietic stem cell transplantation. The diagnoses of invasive fungal infections have historically been made difficult by the need for invasive methods. (1–3)-β-D-glucan testing requires a minimally invasive sample that can be used to aid in the diagnosis of an invasive fungal infection as well as monitor the response to treatment. One disadvantage of (1–3)-β-D-glucan testing is that a positive test alone lacks sufficient sensitivity and specificity for a definitive diagnosis. While formal guidelines for the use of (1–3)-β-D-glucan testing are lacking, this chromogenic assay provides a new opportunity for testing at-risk populations. A review and recommendation for its laboratory and clinical application are provided.
|
---|---|
ln Vivo |
While incorporated within the fungal cell wall (1–3)-β-D-glucan typically exists as an insoluble structure. In the presence of blood or other body fluids, (1–3)-β-D-glucan transforms into single helix, triple helix (most common), or random coil forms and are rendered soluble. This soluble (1–3)-β-D-glucan may be capable of modulating the immune system by inhibiting leukocyte phagocytosis. Details regarding the release and kinetics of soluble (1–3)-β-D-glucan in the systemic circulation or body fluids of patients with proven or probable invasive fungal infections is limited.
|
References |
[1]. Laboratory Medicine, Volume 42, Issue 11, November 2011, Pages 679–685, https://doi.org/10.1309/LM8BW8QNV7NZBROG
|
CAS # |
9012-72-0
|
---|---|
Appearance |
White to off-white solid
|
LogP |
-3.25
|
tPSA |
268.68
|
SMILES |
O1[C@]([H])([C@@]([H])([C@]([H])(C([H])([C@@]1([H])C([H])([H])O[H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])O[H])O[H])OC1([H])[C@@]([H])(C([H])([H])O[H])O[C@@]([H])([C@@]([H])([C@@]1([H])O[H])O[H])O[H]
|
InChi Key |
SPMCUTIDVYCGCK-IIIGWGBSSA-N
|
InChi Code |
InChI=1S/C18H32O14/c19-2-9-6(22)1-7(23)17(29-9)32-16-13(26)11(4-21)30-18(14(16)27)31-15-8(24)5-28-10(3-20)12(15)25/h6-27H,1-5H2/t6-,7+,8-,9+,10+,11+,12+,13+,14+,15+,16-,17-,18-/m0/s1
|
Chemical Name |
(2S,3R,4S,5R,6R)-2-[(2R,3R,4R,5S)-3,5-dihydroxy-2-(hydroxymethyl)oxan-4-yl]oxy-4-[(2S,3R,5S,6R)-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-(hydroxymethyl)oxane-3,5-diol
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO: ~100 mg/mL
H2O: ~20 mg/mL |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (Infinity mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.